New developments in the treatment of castration resistant prostate cancer.

Asian J Androl · 2014 · PMC4104080 · PMID 24759588

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Median OS was not reached for the abiraterone group in the final analysis; the OS was 27.2 months for the placebo group and there was a 25% decrease in the risk of death in the abiraterone group, which showed a trend toward OS improvement.

also in 53,322 other papers

borderline significanceno p-value reported

This study had borderline significance in rejecting the null hypothesis, indicating that there may be cross-resistance between abiraterone and docetaxel, which may be due to docetaxel's effect on AR signaling.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.